Surg-30. using the neurologic assessment in neuro-oncology (nano) scale as a predictive assessment tool for survival in patients with primary glioblastoma

The neurologic assessment in neuro-oncology (NANO) scale is a standardized metric designed to measure neurologic function in neuro-oncology. Current available neuroradiological evaluation criteria fail to use specific clinical criteria for tumor recurrence. Additionally, existing clinical measures of patient performance such as the Karnofsky Performance Scale (KPS) and the Eastern Cooperative Oncology Group (ECOG) are generalized and do not incorporate specific neurologic performance criteria in assessment of the patient, nor are they used to predict glioma progression. Currently, it is not known whether or not the NANO scale can be used as a reliable predictor of survival in patients with glioblastoma (GBM). To evaluate this, we performed a retrospective review of all 78 patients (45 male and 33 female) with primary GBM from January 1, 2010 through December 31, 2012. We applied the NANO scale, KPS, ECOG, MacDonald criteria, and the RANO criteria to patients at the time of diagnosis as well as well as during 3-month, 6-month and 1-year time points to assess for disease prognosis and survival. Patients with a higher initial NANO scale score (4+) demonstrated a worse prognosis when compared to patients with a lower initial score (0-3). Disease progression as defined by the NANO scale was a predictor of decreased survival in patients at 6-months and 1-year. A decrease in KPS >20 points was predictive of survival at 3 and 6-month time points, a two point increase in ECOG ...
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: SURGICAL THERAPY Source Type: research